Трабектедин в лекарственном лечении сарком мягких тканей

1. Coindre JM, Terrier P, Guillou L et al. Predictive value of grade for metastasis development in the main histologic types of adult soft tissue sarcomas: a study of 1240 patients from the French Federation of Cancer Centers Sarcoma Group. Cancer 2001; 91: 1914–26.
2. Pervaiz N, Colterjohn N, Farrokhyar F et al. A systematic meta-analysis of randomized controlled trials for adjuvant chemotherapy for localized resectable soft-tissue sarcoma. Cancer 2008; 113 (3): 573–81.
3. Ferrari A, Gronchi A, Casanova M et al. Synovial sarcoma: a retrospective analysis of 271 patients of all ages treated at a single institution. Cancer 2004; 101(3): 627–34.
4. Eilber FC, Eilber FR, Eckardt J et al. The impact of chemotherapy on the survival of patients with high-grade primary extremity liposarcoma. Ann Surg 2004; 240 (4): 686–95.
5. Nielsen OS, Dombernowsky P, Mouridsen H et al . High-dose epirubicin is not an alternative to standard-dose doxorubicin in the treatment of advanced soft tissue sarcomas: a study of the EORTC Soft Tissue and Bone Sarcoma Group. Br J Cancer 1998; 78: 1634–9.
6. Le Cesne A, Judson I, Crowther D et al. Randomized phase III study comparing conventional-dose doxorubicin plus ifosfamide versus high-dose doxorubicin plus ifosfamide plus recombinant human granulocyte-macrophage colony-stimulating factor in advanced soft tissue sarcomas: A trial of the European Organization for Research and Treatment of Cancer/Soft Tissue and Bone Sarcoma Group. J Clin Oncol 2000; 18: 2676–84.
7. Bokemcyer C, Franzke A, Hartmann JT et al. A Phase 1/11 study of sequential, dose-escalated high-dose ifosfamide plus doxorubicin with peripheral blood stem cell support, for the treatment of patients with advanced soft tissue sarcomas. Cancer 1997; 80: 1221–7.
8. Patel SR, Vadhan-Raj S, Burgess MA et al. Results of two consecutive trials of dose-intensive chemotherapy with doxorubicin and ifosfamide in patients with sarcomas. Am J Clin Oncol 1998; 21: 317–21.
9. Brennan MF, Casper ES, Harrison LB. Soft tissue sarcoma. En: De Vita VT, Hellman S, Rosemberg SA, eds. Cancer: Principles and Practice of Oncology. Philadelphia: Lippincott-Raven, 1997: 1738–88.
10. Van Glabbeke. M, Verwcij J, Judson I et al. Progression-free rate as the principal end-point for Phase 11 trials in soft-tissue sarcomas. Eur J Cancer 2002; 38: 543–9.
11. Roland T, Skeel. Handbook of Cancer Chemotherapy 2003.
12. Choi H, Charnsangavej C, Faria SC et al. Correlation of Computed Tomography and Positron Emission Tomography in Patients With Metastatic Gastrointestinal Stromal Tumor Treated at a Single Institution With Imatinib Mesylate: Proposal of New Computed Tomography Response Criteria ASCO 2007. J Clin Oncol 2007; 25 (13): 1753–9.
13. Van Glabbeke M, van Oosterom AT, Oosterhuis JW et al.: Prognostic factors for the outcome of chemotherapy in advanced soft-tissue sarcoma: an analysis of 2,185 patients treated with antracycline-containing first-line regimens – a European Organization for Research and Treatment of Cancer Soft-Tissue and Bone Sarcoma Group Study. Clin Oncol 1999; 17: 150–7.
14. Pommier Y, Kohlhagen G, Bailly C et al. DNA sequence- and structure-selective alkylation of guanine N2 in the DNA minor groove by ecteinascidin 743, a potent antitumor compound from the carribean tunicate Ecteinascidia Turbinata. Biochemistry 1996; 35: 13 303–9.
15. Schoffski P, Wolter P, Clement P et al. Trabectidin (ET-743): evaluation of its use in advanced soft-tissue sarcoma. Future Oncol 2007; 3 (4): 381–92.
16. Garcia-Carbonero R, Supko JG, Manola J et al.: Phase II and pharmacokinetic studyof ecteinascidin 743 in patients with progressive sarcomas of soft-tissues refractory to chemotherapy. J Clin Oncol 2004; 22: 1480–90.
17. Le Cesne A, Blay JY, Judson I et al: Phase II study of ET-743 in advanced soft-tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) soft-tissue and bone sarcoma group trial. Clin Oncol 2005; 23: 576–84.
18. Yovine A, Riofrio M, Blay JY et al. Phase II study of actenascidin-743 in advanced pretreated soft-tissue sarcoma patients. J Clin Oncol 2004; 22: 890–9.
19. Demetri GD, Chawla SP, von Mehren M et al. Efficasy and safety of trabectidin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after anthracycines and ifosfamide: results of a randomized phase II study of two different schedules. J Clin Oncol 2009; 27.
20. Garcia-Carbonero R, Supko JG, Maki RG et al: Ecteinascidin-743 (ET-743) for chemotherapy-naive patients with advanced soft-tissue sarcomas: multicenter Phase II and pharmacokinetic study. Clin Oncol 2005; 23: 5484–92.
21. Schoffski P. DNA repair functionality as a molecular signature for sensitivity/resistance in sarcoma patients treated with trabectedin. Presented at: 43rd ASCO AnnualMeeting. Los Angeles, CA, USA, April 14–18 2007.
22. Grosso F, Demetri G, Blay JY et al.: Patterns of tumor response to trabectedin in myxoid liposarcomas. Program and Abstracts of the 42nd ASCO Annual Meeting. Atlanta, GA, USA, 2–6 June (2006). Clin Oncol 2006; 24 (18S): 52: Abstr 9511.
23. Walker S, Norwood J, Thornton C, Schaberg D. Trimethoprim-sulfamethoxazole associated rhabdomyolysis in a patient with AIDS: Case report and review of the literature. Am J Med Sci 2006; 331: 33941.
24. Levy RJ, Sparano JA, Khan G. Rhabdomyolysis: An unusual complication of cytotoxic chemotherapy. Med Oncol 1995; 12: 219–22.
25. Koeffler HP, Haskell CM. Rhabdomyolysis as a complication of 5-azacytidine. Cancer Treatment Reports 1978; 62: 573–4.
26. Reinhold U, Hartl C, Hering R et al. Fatal rhabdomyolysis and multiple organ failure associated with adjuvant high-dose interferon alfa in malignant melanoma. Lancet 1997; 349: 540–1.
27. Ceribelli A, Cecere FL, Milella M et al. Severe rhabdomyolysis associated with pemetrexed based chemotherapy. Lancet Oncol 2006; 7: 353.
28. Truica CI, Frankel SR. Acute rhabdomyolysis as a complication of cytarabine chemotherapy for acute myeloid leukemia: Case report and review of literature. Am J Hematol 2002; 70: 320–3.
29. Cibeira MT, Mercadal S, Arenillas L et al. Bortezomib induced rhabdomyolysis in multiple myeloma. Acta Haematol 2006; 116: 203–6.

В.А.Горбунова, М.Д.Алиев, А.А.Феденко, Б.Ю.Бохян, И.А.Истомин

ГУ Российский онкологический научный центр им. Н.Н.Блохина РАМН, Москва